MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fmed.2023.1073025

Медицинская библиотека · Frontiers in medicine · 2023

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients.

Sugimoto Ryosuke, Iwasa Motoh, Eguchi Akiko, Tamai Yasuyuki, Shigefuku Ryuta, Fujiwara Naoto, Tanaka Hideaki, Kobayashi Yoshinao, Ikoma Jiro, Kaito Masahiko, Nakagawa Hayato

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND/AIMS: Pemafibrate is a selective peroxisome proliferator-activated receptor α modulator that improves serum alanine aminotransferase (ALT) in dyslipidemia patients. Pemafibrate was reported to reduce ALT in non-alcoholic fatty liver disease (NAFLD) patients, but efficacy was not clearly elucidated due to the small size of previous study populations. Therefore, we explored pemafibrate efficacy in NAFLD patients.

METHODS

We retrospectively evaluated pemafibrate efficacy on liver enzymes (n = 132) and liver shear wave velocity (SWV, n = 51) in NAFLD patients who had taken pemafibrate for at least 24 weeks.

RESULTS

Patient ALT levels were decreased from 81.0 IU/L at baseline to 48.0 IU/L at week 24 (P < 0.0001). Serum levels of aspartate aminotransferase (AST), γ-glutamyl transpeptidase (γ-GTP) and triglyceride (TG) were significantly decreased, and high-density lipoprotein cholesterol and platelet count were significantly increased, with no change in body weight being observed. Study participant SWV values decreased from 1.45 m/s at baseline to 1.32 m/s at week 48 (P < 0.001). Older age (P = 0.035) and serum TG levels (P = 0.048) were significantly associated with normalized ALT. Changes in AST, ALT, γ-GTP and body weight were significantly correlated with change in SWV.

CONCLUSION

Pemafibrate significantly improves liver function, serum TG and liver stiffness in NAFLD patients. Pemafibrate is a promising therapeutic agent for NAFLD and may be a candidate for NAFLD patients with elevated TG.

Для цитирования: Sugimoto Ryosuke, Iwasa Motoh, Eguchi Akiko, Tamai Yasuyuki, Shigefuku Ryuta, Fujiwara Naoto, Tanaka Hideaki, Kobayashi Yoshinao, Ikoma Jiro, Kaito Masahiko, Nakagawa Hayato. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients.. Frontiers in medicine. 2023. DOI: 10.3389/fmed.2023.1073025.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.